Severe Acute Respiratory Syndrome Clinical Trial
Official title:
A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS
The purpose of this trial is to conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an antiviral and immunomodulator in asymptomatic subjects with recent exposure to a person with severe acute respiratory syndrome (SARS) or possible SARS. The primary objective of this pilot study is to determine an Alferon LDO dose level that increases or upregulates genes known to be mediators of interferon response. Secondary endpoints include the development of SARS symptomatology, rate of hospitalization, and mortality rate. In the event that no subjects with recent exposure to a person with SARS or possible SARS are available, this study will be conducted with 10 normal volunteers.
Status | Completed |
Enrollment | 10 |
Est. completion date | April 2006 |
Est. primary completion date | April 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. 18-80 years of age. 2. Asymptomatic with close contact within the last 5 days with a person known to have possible SARS (SARS RUI-2 (SARS Report under investigation), RUI-3, RUI-4) or probable SARS or confirmed SARS using the Centers for Disease Control and Prevention (CDC) Supplement B: SARS Surveillance, Appendix B1: Revised Council of State and Territorial Epidemiologists (CSTE) SARS Surveillance Case Definition (Attachment II). 3. Oral temperature < 100.4°F (<38°C) 4. Subjects must be asymptomatic with regard to SARS related clinical symptoms including any signs of a respiratory illness. 5. Serum creatinine = 1.5 x ULN (upper limit of normal); serum bilirubin = 1.5 x ULN. 6. Total white blood cells (WBC) = 3000/mm3, platelet count = 100,000/mm3 and granulocytes = 1500 mm3. 7. Hemoglobin > 10.0 g/dl. 8. ALT (alanine aminotransferase) and AST (aspartate aminotransferase) < 4 times upper normal limit. 9. C-reactive protein serum level in normal range 10. Serum albumin > 2.0 g/dl. 11. Written informed consent. 12. Females must either be of non-child bearing potential, or utilize an effective form of contraception and have a negative pregnancy test prior to randomization. Exclusion Criteria: 1. Pregnant or nursing women, or women not using an effective form of contraception. 2. Less than 18 years of age. 3. Active intravenous (IV) drug users. 4. Receipt of any immunosuppressive agent, chemotherapy, or systemic steroids within 45 days of study entry. 5. Receipt of any immunomodulator such as BCG (bacille Calmette Guerin) vaccine, isoprinosine, or similar experimental agents within 45 days of study entry. 6. Evidence of HIV or other viral infections including chronic hepatitis, or other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular, neurological, or psychiatric disorder that would limit the subject's ability to complete the study period. 7. Unlikely or unable to comply with the requirements of the protocol. 8. Patients unwilling or unable to give informed consent. 9. Patients on any other concurrent experimental medication. 10. Patients using any form of interferon therapy during the 6 weeks prior to study entry. 11. Hospitalized subjects, or those with an active viral infection other than possible SARS, within 2 weeks of study entry. 12. Transfusion dependent subjects (subjects requiring > 1 unit of packed RBC [red blood cells] per month within the 3 months prior to study entry). |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Hong Kong | Princess Margaret Hospital | Lai Chi Kok | Kowloon |
Lead Sponsor | Collaborator |
---|---|
Hemispherx Biopharma |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gene expression analysis | Increased expression of genes known to be mediators of interferon response. | Days 0, 2, 6, 11, 12, 15, 20 and 40 | No |
Secondary | SARS CoV Antibody | Development of clinical SARS-CoV symptomatology | Days 0, 15, 20 and 40 | Yes |
Secondary | SARS-CoV infection | Hospitalization for SARS-CoV infection and Death | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Recruiting |
NCT04480333 -
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
|
Phase 1 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Not yet recruiting |
NCT04386070 -
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
|
Phase 3 | |
Withdrawn |
NCT00073086 -
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)
|
N/A | |
Active, not recruiting |
NCT04527432 -
COVID-19 Health Professional Impact Study
|
N/A | |
Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|
||
Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04376684 -
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
|
Phase 2 | |
Completed |
NCT04395144 -
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
|
N/A | |
Completed |
NCT04357730 -
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
|
Phase 2 | |
Completed |
NCT04425213 -
Obesity and Mortality of Critically Ill Patients With COVID-19
|
||
Completed |
NCT04425863 -
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
|
||
Completed |
NCT06287554 -
Effect of Early Implementation of Prone Positioning
|
||
Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
Completed |
NCT03225807 -
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
|
||
Recruiting |
NCT04381819 -
Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
|